Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company focused on autoimmune, inflammatory, and other immune-mediated diseases. Through these filings, investors can review how the company reports material events, financing transactions, and governance changes that affect holders of STTK common stock.
Shattuck’s Form 8-K current reports provide details on topics such as private placements of common stock and warrants, the terms of securities purchase agreements, and related registration rights agreements. These filings describe the structure of pre-funded warrants and common warrants, exercise price provisions, beneficial ownership limitations, and expected gross proceeds, as well as the company’s plans to register resales of the underlying shares.
Other 8-K filings furnish press releases announcing quarterly financial results, including research and development and general and administrative expenses, collaboration or license revenue, and net loss figures. While these press releases are often furnished rather than filed for Exchange Act purposes, they offer insight into Shattuck’s cash position and its expectations about how long existing capital and financing arrangements may support operations, subject to the risks noted in its periodic reports.
Filings also address governance matters, such as the resignation and appointment of directors, changes in board size, and committee assignments. For example, Shattuck has reported the addition of new directors associated with a significant private placement and described the rights of certain investors to designate board members under letter agreements.
By reviewing these SEC documents alongside AI-powered summaries, readers can quickly understand the key terms of Shattuck’s financings, the regulatory status of its securities, and the corporate actions that shape its capital structure and oversight. This filings archive complements Shattuck’s scientific and clinical disclosures by showing how those activities are reflected in its official regulatory reporting.
Shattuck Labs, Inc. reported that officer Stephen Stout received a stock option award for 351,400 shares of common stock at an exercise price of $4.75 per share on January 10, 2026. The option vests over time, with one quarter vesting on January 10, 2027 and the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 4,153 shares of common stock were withheld at $4.75 per share in a transaction coded “F,” typically used for tax withholding, leaving Stout with 82,122 common shares held directly after the transaction.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported an equity award and a share disposition. On January 10, 2026, DeYoung was granted a stock option to purchase 381,600 shares of common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option vests on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to continued service. On the same date, 5,699 shares of common stock were disposed of at $4.75 per share, after which DeYoung directly owned 75,766 shares of common stock.
Shattuck Labs, Inc. reported an equity award to its Chief Technical Officer, Abhinav A. Shukla. On January 10, 2026, he received a stock option covering 315,500 shares of Shattuck Labs common stock at an exercise price of $4.75 per share, reported as a derivative security held directly.
The option has a long-term vesting schedule: one quarter of the shares will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, conditioned on his continued service with the company. The option expires on January 10, 2036, giving him a multi-year window to exercise once vested.
Shattuck Labs, Inc. reported an insider equity transaction by its Chief Medical Officer, Pandite Arundathy N. On January 10, 2026, she was granted an option to purchase 487,800 shares of common stock at an exercise price of $4.75 per share. The option vests over time: one quarter of the shares on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on her continued service.
On the same date, she disposed of 6,851 shares of common stock at $4.75 per share, and reported owning 199,414 common shares directly after this transaction.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported new equity compensation and a related share withholding. On January 10, 2026, he received a stock option to purchase 549,800 shares of Shattuck Labs common stock at an exercise price of $4.75 per share. According to the vesting terms, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, contingent on his continued service.
On the same date, 6,660 shares of common stock were disposed of at $4.75 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes upon vesting or exercise. After this transaction, Neill directly beneficially owned 230,813 shares of common stock and 549,800 stock options.
Shattuck Labs, Inc. reported that Chief Executive Officer and director Taylor Schreiber received a new stock option grant on January 10, 2026. The option gives him the right to buy 1,548,300 shares of Shattuck Labs common stock at an exercise price of $4.75 per share and expires on January 10, 2036.
According to the vesting schedule, one quarter of the option will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, as long as he continues serving the company. After this grant, he beneficially owns 1,548,300 derivative securities directly.
Shattuck Labs, Inc. has filed a shelf registration to offer up to $200,000,000 in aggregate of common stock, preferred stock, debt securities, warrants and units from time to time. Each offering will have its own prospectus supplement detailing specific terms, pricing and the method of sale, which may include underwritten offerings, direct sales or at-the-market transactions on The Nasdaq Global Select Market under the symbol STTK. The company develops potential treatments for inflammatory and immune-mediated diseases, led by its SL-325 antibody program. Net proceeds from future offerings are expected to fund ongoing and planned clinical trials, development of additional product candidates, and general corporate and working capital needs, with possible use for licensing or acquisitions.
Shattuck Labs (STTK) filed an 8-K/A (Amendment No. 1) to correct typographical errors in a previously filed 8-K. The amendment covers Item 2.02 relating to a press release announcing financial results for the quarter ended September 30, 2025, which is furnished as Exhibit 99.1.
The company notes that, under General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed. The filing also lists Exhibit 104, the cover page formatted in Inline XBRL.
Shattuck Labs (STTK) reported Q3 2025 results showing a smaller loss as operating expenses declined and it recognized license revenue. License and collaboration revenue was $1,000, versus $2,997 a year ago, reflecting a one-time license to Kayak Therapeutics. Research and development expense fell to $7,618 from $16,313, and general and administrative expense was $4,098 versus $4,604. Net loss narrowed to $10,056 from $16,675.
Cash and cash equivalents were $42,548 and investments were $43,584 as of September 30, 2025, for total liquid resources of about $86.1 million. Management states this is sufficient to fund projected operations for at least the next twelve months. During August 2025, the company raised $44,480 net in a private placement of common stock, pre-funded warrants, and common stock warrants tied to future clinical data disclosure milestones. Shares outstanding were 63,151,789 at quarter-end; the company disclosed 63,279,843 outstanding as of October 23, 2025.